| Q36189562 | A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia |
| Q47248937 | Antigen Analysis of Pre-Eclamptic Plasma Antibodies Using Escherichia Coli Proteome Chips |
| Q37148121 | Association between PAPP-A and placental thickness |
| Q35756049 | Biochemical markers for prediction of preclampsia: review of the literature. |
| Q38040182 | Biomarkers in pre-eclampsia: a novel approach to early detection of the disease |
| Q92563835 | Biosensors for Detection of Human Placental Pathologies: A Review of Emerging Technologies and Current Trends |
| Q46306526 | Blood laboratory testing for early prediction of preeclampsia: chasing the finish line or at the starting blocks? |
| Q33923716 | Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? |
| Q90538941 | Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns |
| Q26801503 | Combined Screening for Early Detection of Pre-Eclampsia |
| Q34009454 | Comparison of different blood collection, sample matrix, and immunoassay methods in a prenatal screening setting |
| Q34919926 | Diagnosis and management of fetal growth restriction |
| Q26781355 | Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis |
| Q36125098 | Early detection of maternal risk for preeclampsia |
| Q38619000 | Early serum markers of pre-eclampsia: are we stepping forward? |
| Q92980466 | Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia |
| Q54217569 | Evaluation of biochemical markers combined with uterine artery Doppler parameters in fetuses with growth restriction: a case-control study. |
| Q38210332 | First trimester screening can predict adverse pregnancy outcomes |
| Q33956332 | First trimester serum analytes, maternal characteristics and ultrasound markers to predict pregnancies at risk for preterm birth |
| Q35124240 | First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia |
| Q34111720 | First-trimester placental ultrasound and maternal serum markers as predictors of small-for-gestational-age infants |
| Q35988764 | First-trimester prediction of preeclampsia in nulliparous women at low risk |
| Q36904026 | First-trimester serum analytes, biophysical tests and the association with pathological morphometry in the placenta of pregnancies with preeclampsia and fetal growth restriction |
| Q85029222 | First‐trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early‐onset pre‐eclampsia |
| Q35202265 | Framing postpartum hemorrhage as a consequence of human placental biology: an evolutionary and comparative perspective |
| Q49447471 | Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138. |
| Q28081459 | Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia |
| Q26823092 | Galectins: guardians of eutherian pregnancy at the maternal-fetal interface |
| Q39006055 | Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia |
| Q39260574 | Hypertension in pregnancy |
| Q58588403 | Impact of vitamin D and vitamin D receptor on the trophoblast survival capacity in preeclampsia |
| Q45418742 | Longitudinal trends in fetoplacental biochemical markers, uterine artery pulsatility index and maternal blood pressure during the first trimester of pregnancy |
| Q51454988 | New Predictive Model at 11+0 to 13+6 Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction. |
| Q38080626 | Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis |
| Q28386182 | Novel biomarkers for predicting preeclampsia |
| Q37852802 | Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis |
| Q36065327 | PP13 and PAPP-A in the First and Second Trimesters: Predictive Factors for Preeclampsia? |
| Q33393566 | PP13 mRNA expression in trophoblasts from preeclamptic placentas |
| Q28742192 | PP13, maternal ABO blood groups and the risk assessment of pregnancy complications |
| Q42373442 | Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function |
| Q55692173 | Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits. |
| Q38089817 | Physiological and pathophysiological roles of placental aminopeptidase in maternal sera: possible relation to preeclampsia and preterm delivery |
| Q36847097 | Placental Expression Patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in Cases of Intrauterine Growth Restriction (IUGR). |
| Q91638842 | Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response |
| Q26861380 | Placental Protein 13 (PP13) - A Placental Immunoregulatory Galectin Protecting Pregnancy |
| Q56794716 | Placental Protein 13 and Decidual Zones of Necrosis: An Immunologic Diversion That May be Linked to Preeclampsia |
| Q87113935 | Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes |
| Q50992588 | Placental protein 13 (PP13)-induced vasodilation of resistance arteries from pregnant and nonpregnant rats occurs via endothelial-signaling pathways. |
| Q37416997 | Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. |
| Q55689583 | Placental protein 13: An important biological protein in preeclampsia. |
| Q37278804 | Potential markers of preeclampsia--a review |
| Q98162346 | Pre-eclampsia predictive ability of maternal miR-125b: a clinical and experimental study |
| Q37362662 | Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection |
| Q37479314 | Prediction and prevention of preeclampsia |
| Q26864872 | Predictive factors for intrauterine growth restriction |
| Q37725865 | Risk factors and prediction of preeclampsia |
| Q33783531 | Role of biomarkers in early detection of preeclampsia |
| Q26798011 | Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis |
| Q38653051 | Systematic review on first trimester three-dimensional placental volumetry predicting small for gestational age infants |
| Q26798193 | The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia |
| Q37958705 | The roles of the immune system in women's reproduction: evolutionary constraints and life history trade-offs. |